Mike Morris Selected to the Stanley K. Lacy Executive Leadership Series® Class XLIX
July 31, 2025
Congratulations to Mike Morris on his selection for the prestigious Stanley K. Lacy Executive Leadership Series®. This 10-month program, renowned for its competitiveness, is a cornerstone of Leadership Indianapolis. Class members are selected for their significant community involvement and professional…
Read MoreProtecting Your Innovations: The Importance of Intellectual Property
July 30, 2025
Understanding your company’s intellectual property assets is crucial for safeguarding your innovations. These assets might include unique methods for creating or delivering products, as well as novel combinations of existing devices. If your business involves new products, processes, or improvements…
Read MoreFederal Circuit Orders New Trial on LED Tube Lamp Patents After Exclusion of Key Evidence
July 28, 2025
Jiaxing Super Lighting Elec. Appliance, Co., v. CH Lighting Tech. Co Authored by: Jeremy J. Justrowsky In a significant patent dispute over LED tube lamp technology, the Federal Circuit has sent the case of Jiaxing Super Lighting Electric Appliance Co.,…
Read MoreFederal Circuit Dodges Patent Royalty Battle, Transfers Case Over Jurisdiction Hiccup
July 25, 2025
Acorda Therapeutics, Inc. v. Alkermes PLC Authored by: Jeremy J. Gustrowsky In the world of pharmaceutical partnerships, Acorda Therapeutics and Alkermes PLC once teamed up to bring Ampyra—a drug helping multiple sclerosis patients walk better—to market. Alkermes held a key…
Read MoreSunkist Prevails in Trademark Dispute Over “KIST” Soda Branding
July 23, 2025
Sunkist Growers, Inc. v. Intrastate Distribs., Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the U.S. Court of Appeals for the Federal Circuit reversed a ruling by the Trademark Trial and Appeal Board (TTAB) and sided with Sunkist…
Read MoreFederal Circuit Clarifies Limits of Interference Estoppel in Patent Reviews: IGT v. Zynga
July 22, 2025
IGT v. Zynga Inc Authored by: Jeremy J. Gustrowsky In a significant decision for patent litigation and the gaming industry, the Federal Circuit affirmed the unpatentability of several claims in IGT’s U.S. Patent No. 7,168,089, which covers secure software transfers…
Read MorePatent Infringement Win Overturned: Colibri Heart Valve Loses $106 Million Verdict Against Medtronic
July 18, 2025
Colibri Heart Valve LLC v. Medtronic Corevalve, LLC Authored by: Jeremy J. Gustrowsky In a significant patent law decision, the Federal Circuit reversed a $106 million jury verdict in favor of Colibri Heart Valve LLC against Medtronic CoreValve, LLC, ruling…
Read MoreUnderstanding Your Company’s Intellectual Property Assets
July 16, 2025
What makes up your company’s intellectual property assets? At the core of every business lies proprietary information, which often serves as a crucial competitive advantage. This can encompass a wide range of items, such as customer data, product designs, strategic…
Read MoreFederal Circuit Clarifies Use of Applicant Admitted Prior Art in Patent Challenges
July 14, 2025
Shockwave Med., Inc. v. Cardiovascular Sys Authored by: Jeremy J. Gustrowsky In the recent case of Shockwave Medical, Inc. v. Cardiovascular Systems, Inc., the Federal Circuit addressed how “Applicant Admitted Prior Art” (AAPA) can be used in patent challenges before…
Read MorePatent Board Denies Rehearing for DeepMind’s Machine Learning Patent Application
July 14, 2025
USPTO Authored by: Jeremy J. Gustrowsky In a recent decision, the Patent Trial and Appeal Board (PTAB) denied a request for rehearing from DeepMind Technologies Limited regarding their U.S. Patent Application No. 16/319,040. The application, which focuses on improving machine…
Read MoreFederal Circuit Upholds Janssen’s Invega Sustenna Patent Against Obviousness Challenge
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a significant decision for pharmaceutical patent holders, the Federal Circuit has affirmed the validity of Janssen Pharmaceuticals’ U.S. Patent No. 9,439,906, which covers specific dosing regimens…
Read MoreFederal Circuit Clarifies Obviousness Standards for Drug Dosing Patents
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit provided important guidance on how courts should analyze the obviousness of pharmaceutical dosing regimen patents. The case involved Janssen’s U.S.…
Read More